Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a phase three study to evaluate the safety and efficacy of Pradefovir treatment in
chronic hepatitis B patients. Subject will be randomized to Pradefovir group and TDF group at
a ratio of 2:1. Treatment duration will be 96w in randomization and followed by 48w in open.
The interim analysis will be conducted when all subject completed the first 48-week
treatment.